Mayne Pharma Group Limited (MYX) Scheme Implementation Deed and AGM Update
The Australian Securities Exchange (ASX) announced that Mayne Pharma Group Limited has entered into a Scheme Implementation Deed (SID) with Gedeon Richter Plc. The scheme is a cash‑based acquisition in which Gedeon Richter will purchase all shares of Mayne Pharma at A$6.40 per share.Key financial terms
- The offer values Mayne Pharma’s equity at approximately A$604 million, representing a 99.4 % premium to the pre‑announcement share price.
- The Board has unanimously recommended that shareholders vote in favour of the scheme in the absence of a superior proposal, subject to the Independent Expert confirming that the scheme is in the best interests of shareholders.
- The CEO, Mr. Aaron Gray, and CFO, Mr. Griffin Buchanan, will host a webcast of the transaction at 11:00 am AEDT (7:00 pm US Eastern Time) on 16 November 2026.
AGM Update – Withdrawal of Dr Brett Wells Resolution
An update to the AGM notice, issued on 17 November 2026, states that Dr Brett Wells has requested the withdrawal of resolution 4 (his election as a director) from the agenda. The withdrawal is linked to the recent announcement of the scheme. The resolution will therefore not be presented to shareholders. All other items listed in the AGM notice will proceed as originally scheduled. The AGM is set for 10:00 am (Melbourne time) on 20 November 2026.
Market Context
On 17 November 2026, the ASX 200 index fell 1.79 %, largely influenced by a decline in commodity‑related stocks following the unwinding of AI‑related positions on Wall Street. This broader market movement coincided with the disclosure of Mayne Pharma’s scheme, which may have contributed to the share price decline before the premium offer was announced.
Company Profile
Mayne Pharma Group Limited (ASX: MYX) is a health‑care company headquartered in Salisbury South, Australia, specializing in the development and manufacturing of oral pharmaceuticals, including branded and specialty generics and active pharmaceutical ingredients. The company’s share price on 16 November 2026 closed at A$6.01, with a 52‑week high of A$6.04 and a 52‑week low of A$2.04. Its market capitalisation stands at A$262.87 million and it trades at a price‑earnings ratio of 21.96.




